Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Xilio Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 33 | 2 | 35 | +4 |
| Shares | 16.0M | 1.48M | 25.9M | +11.4M (+78.6%) |
| Value | $12.6M | $1.17M | $24.7M | +$13.3M (+116.3%) |
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gilead Sciences, Inc. | 9,105,451 | $8.70M | 0.56% |
| Merck & Co., Inc. | 1,483,758 | $1.42M | 0.55% |
| AJU IB Investment Co., Ltd. | 667,742 | $637.7K | 0.62% |
| Trustees of Columbia University in the City of New York | 249,635 | $238.4K | 0.04% |
| Raymond James Financial Inc | 50,086 | $47.8K | 0.00% |
| Susquehanna International Group, LLP | 49,093 | $46.9K | 0.00% |
| Aptus Capital Advisors, LLC | 41,000 | $39.2K | 0.00% |
| Citadel Advisors LLC | 40,316 | $38.5K | 0.00% |
| Federation des caisses Desjardins du Quebec | 3,300 | $3.15K | 0.00% |
Sold out (5)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Two Sigma Securities, LLC | 44,445 | $35.0K |
| Engineers Gate Manager LP | 32,752 | $25.8K |
| Millennium Management LLC | 20,655 | $16.3K |
| Avantax Planning Partners, Inc. | 20,483 | $16.1K |
| Dunhill Financial, LLC | 10,274 | $8.09K |
Not filed for Q4 2024 yet (2)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $1.14M |
| Raymond James & Associates | 38,825 | $30.6K |